AOD 9604 Complete Research Profile: A Research-Use-Only Science Guide to the hGH 176-191 Fragment

AOD 9604 is a research-grade reference peptide supplied strictly for in-vitro and laboratory research use only. It is not for human or animal consumption, is not FDA approved for any use represented here, and is not a drug, supplement, cosmetic, or treatment for any metabolic or weight-related condition. This page is third-person science education about what researchers investigate when they study AOD 9604 in cell cultures and animal models. It does not describe or endorse taking, dosing, or administering any substance, and any health question belongs with a licensed clinician.

What AOD 9604 Is

AOD 9604 is a synthetic peptide corresponding to the carboxyl-terminal region of human growth hormone, specifically residues 176 to 191, with a tyrosine added at the amino terminus of the fragment. The name is an abbreviation of anti-obesity drug candidate 9604, a designation from its early development history rather than a description of any established property. In the current research literature it is treated as a growth hormone fragment studied for lipid-handling mechanisms, and nothing more than that.

The scientific interest in this molecule rests on a single structural fact: it is a fragment, not the whole hormone. Human growth hormone is a 191-residue protein whose actions include growth signaling, glucose counter-regulation, and IGF-1 induction, all of which depend on the intact molecule engaging the growth hormone receptor. A 16-residue fragment cannot fold the way the parent protein does and does not reproduce that receptor engagement, which is why the fragment is studied as a way to ask whether the lipid-related portion of growth hormone biology can be separated from the rest.

On this page AOD 9604 is treated entirely as laboratory science. The material supplied by Peptides Factory Direct is a reference compound for controlled research, not a product for personal use. For the underlying biology of how short peptides act as signaling molecules, see the primer on what peptides are, and for the wider set of compounds studied around lipid metabolism see the fat loss peptides category.

• Class: synthetic fragment of human growth hormone, residues 176 to 191, with an N-terminal tyrosine.
• Research status: reference material for in-vitro and animal study only, never a medicine, supplement, or cosmetic.
• Primary research interest: lipolysis and lipogenesis mechanisms in adipocyte models, separated from growth hormone receptor signaling.
• Catalog listing and specifications: AOD 9604.

The Fragment Hypothesis and Why It Matters

Growth hormone influences fat metabolism, but it also raises IGF-1, affects glucose handling, and drives tissue growth. For a researcher trying to understand the lipid-related arm of that biology, the intact hormone is a blunt instrument: every observed metabolic change carries the possibility that it came from one of the other effects rather than from a direct action on fat cells. Work in the 1990s on structure-function relationships in growth hormone asked whether particular regions of the sequence carried particular activities, and the C-terminal region became the candidate for the lipid-related component.

AOD 9604 was constructed to test that separation. If a short C-terminal fragment reproduces lipid-handling effects in adipocyte models while failing to activate the growth hormone receptor and failing to raise IGF-1, then those two arms of growth hormone biology are at least partly dissociable, and the fragment becomes a cleaner experimental tool for studying the lipid arm on its own. That is the intellectual content of the molecule, and it is why it appears in mechanistic comparisons rather than in efficacy narratives.

It is worth being precise about what such a result would and would not establish. Demonstrating that a fragment acts on cultured adipocytes without engaging the growth hormone receptor is a statement about mechanism in a dish. It is not a statement about body composition, weight, or metabolic health in a person, and the published preclinical record on this compound has not been matched by convincing human outcome evidence. Both halves of that sentence belong in any honest summary.

Lipolysis and Lipogenesis in Adipocyte Models

The two processes at the center of AOD 9604 research are lipolysis, the enzymatic breakdown of stored triglyceride into glycerol and free fatty acids, and lipogenesis, the synthesis and storage of new lipid. They are opposing arms of the same balance sheet, and a compound can in principle shift the balance by pushing on either one. Research on this fragment examines both, which is a more informative design than measuring only one direction.

In cell-culture work the standard system is a differentiated adipocyte line, commonly 3T3-L1 cells taken through a differentiation protocol, or primary adipocytes isolated from animal tissue. Lipolysis is quantified by measuring glycerol and free fatty acid release into the medium, since glycerol has no significant reuptake pathway in adipocytes and therefore serves as a reliable stoichiometric marker of triglyceride breakdown. Lipogenesis is assessed by labeled substrate incorporation into the lipid fraction or by the activity and expression of lipogenic enzymes.

Animal-model work extends these readouts to whole tissue, measuring fat pad mass, tissue triglyceride content, and expression panels for lipid-handling genes, alongside circulating markers. A well-designed study in this area also measures IGF-1 and glucose, not as outcomes of interest but as negative controls: the hypothesis behind the fragment predicts that those should not move, and a study that does not check has not tested its own premise.

What Adipocyte Culture Results Do Not Show

A change in glycerol release from a cultured cell line is a measurement of an isolated biochemical process under controlled conditions. It does not account for appetite, energy expenditure, hormonal counter-regulation, nutrient partitioning, or any of the systemic factors that determine what happens to fat mass in a living organism. Cell-culture and rodent findings in this field are mechanistic leads, not evidence of a weight or body-composition effect in people, and any question about human metabolic health belongs with a licensed clinician rather than with a research supplier.

Receptor Questions and an Unsettled Mechanism

One of the more scientifically interesting features of AOD 9604 is that its mechanism is not fully resolved. Because the fragment does not activate the growth hormone receptor in the way the intact hormone does, its reported effects on adipocytes require a different explanation, and the literature has proposed several without converging on one. Candidate accounts have included effects on beta-adrenergic signaling in adipose tissue and interaction with pathways governing lipogenic enzyme expression, but none of these is settled.

That ambiguity is a legitimate reason the compound continues to appear in research contexts, and it is also a reason to read claims about it carefully. A molecule with a well-characterized receptor can be studied with agonists, antagonists, and knockouts that pin an effect to a pathway. A molecule without an identified receptor cannot be interrogated that way, so the standard of evidence for attributing any observed change to a specific mechanism is correspondingly harder to meet.

For researchers this shapes experimental design. Studies of poorly characterized compounds lean more heavily on comprehensive negative controls, on dose-response relationships that behave sensibly, and on replication across more than one model system. It also means the honest description of AOD 9604 in any literature summary is a fragment with reported effects in preclinical lipid models and an incompletely defined mechanism, which is a different statement from a fat-loss peptide.

How AOD 9604 Sits Against Other Metabolic Research Compounds

AOD 9604 is often grouped with other compounds studied in metabolic research, but the mechanisms involved are entirely different and the grouping is one of research topic rather than of pharmacology. Incretin analogs such as semaglutide and tirzepatide act at GLP-1 and GIP receptors, influencing insulin secretion and gastric handling through well-mapped G-protein-coupled receptor pathways. The receptor biology behind that class is set out in the explainer on GLP-1, GIP, and glucagon.

Tesamorelin, by contrast, is a GHRH analog that engages the growth hormone axis at the pituitary, upstream of everything AOD 9604 is proposed to touch. Setting a fragment with no established receptor next to an incretin agonist with a crystallized receptor structure and a GHRH analog with a defined pituitary target is exactly the kind of comparison that clarifies how uneven the evidence base across this space actually is.

That contrast is why researchers include comparator arms rather than studying a single compound alone. Placing AOD 9604 alongside a compound with a defined receptor lets an investigator distinguish effects specific to the fragment from general features of the assay system. Related mechanistic questions across this space are collected in the GLP-1 and metabolic peptide questions.

Handling, Solubility, and Stability

AOD 9604 is supplied as a lyophilized powder, the standard format for research peptides because the dry state limits hydrolysis and oxidation during shipping and storage. Sealed lyophilized vials are generally held frozen for long-term storage and kept away from light and moisture. Once reconstituted, the peptide is in solution and degrades considerably faster than it does in the dry state.

Reconstitution in the laboratory typically uses bacteriostatic or sterile water introduced slowly down the inside wall of the vial rather than directly onto the powder cake, followed by gentle swirling. Shaking introduces shear forces and air-liquid interfaces that promote aggregation. Reconstituted material is refrigerated, protected from light, and not subjected to repeated freeze-thaw cycles, each of which costs measurable integrity.

Short peptides such as this one are relatively short-lived in biological media, a property that shapes how culture experiments are timed and how often treatment medium is refreshed. The general reasoning is covered in the explainer on peptide half-life, and concentration math for research preparations can be checked with the peptide reconstitution calculator. None of this describes administration to a person or an animal; it describes preparation of a reference material for bench work.

• Store sealed lyophilized vials frozen, protected from light and moisture.
• Reconstitute gently down the vial wall with an appropriate sterile diluent, then swirl rather than shake.
• Refrigerate reconstituted solution, protect from light, and avoid repeated freeze-thaw cycles.
• Record lot number, diluent, concentration, and preparation date so results remain traceable.

What Researchers Measure

In adipocyte culture the core readouts are glycerol and free fatty acid release as markers of lipolysis, labeled substrate incorporation into lipid as a marker of lipogenesis, and expression or activity of the enzymes that govern both directions, including hormone-sensitive lipase and lipogenic enzymes such as fatty acid synthase. Time courses and dose-response curves establish whether an observed change behaves like a real pharmacological effect or like assay drift.

Because the defining hypothesis behind the fragment is dissociation from growth hormone receptor activity, the negative controls carry as much weight as the positive readouts. Studies measure IGF-1 induction, growth hormone receptor activation markers, and glucose handling specifically to demonstrate that these do not move. A study reporting a lipid effect without those measurements has not distinguished a fragment-specific action from a general growth hormone effect.

Animal studies add fat pad mass, tissue triglyceride content, food intake, and body weight trajectories, with food intake being an important control because a change in eating behavior can produce fat-mass changes that have nothing to do with adipocyte biochemistry. Across all designs, vehicle controls and a comparator compound remain the minimum standard for attributing any change to the test article.

Why Purity and a Certificate of Analysis Matter

A peptide is defined by its sequence, and a synthesis that runs at 90 percent purity contains roughly 10 percent of something that is not the intended molecule. For a fragment such as this one, the most likely impurities are truncated chains missing residues from either end, and a truncated version of a fragment is a different molecule with different or absent activity. In an experiment where the hypothesis rests on a specific short sequence carrying a specific property, sequence fidelity is not a quality nicety; it is the experiment.

This is why a certificate of analysis is a research requirement rather than a marketing document. High-performance liquid chromatography establishes purity by separating the sample and quantifying the main peak against everything else present, and mass spectrometry confirms that the main peak carries the expected molecular weight for the intended sequence. Purity without identity confirmation is incomplete, because a very pure sample of the wrong molecule still passes an HPLC threshold. The reasoning is set out on the certificate of analysis page and in the purity testing and COA questions.

Researchers evaluating a supplier should expect lot-specific documentation rather than a generic sheet, because purity is a property of a synthesis run and not of a product name. Current catalog availability is listed on the order page, and broader background reading sits in the learn library. All material is supplied for laboratory research use only and is not for human or animal consumption.

Frequently asked questions

All guides · Order research peptides

External references: U.S. Food and Drug Administration · Peptide (Wikipedia)